Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) - Tyrosine Kinase Inhibitors (TKI) in Elderly Patients With EGFR Mutation-Positive N...

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Anticancer Agents
Personalised/Precision Medicine
Geriatric Oncology
Presenter Yuki Takeyasu
Citation Annals of Oncology (2018) 29 (suppl_9): ix150-ix169. 10.1093/annonc/mdy425
Authors Y. Takeyasu1, Y. Goto1, R. Morita1, J. Sato1, S. Murakami1, H. Horinouchi1, Y. Fujiwara1, S. Kanda1, N. Yamamoto1, Y. Ohe2
  • 1Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2Department Of Thoracic Oncology, National Cancer Center Hospital, Tokyo/JP



In response to aging society, age distribution of the lung cancer patient is getting older. Opportunity to treat elderly with EGFR-TKIs is increasing. Most of the clinical trial for patients with EGFR mutation include the elderly, however, proportion of those is relatively low especially in patients over 75 years old.


We analyzed the efficacy and safety of EGFR-TKIs in patients with EGFR mutated NSCLC who were ≥75 years old and treated at National Cancer Center Hospital, between 2009 and 2018. We compared the efficacy and safety in patients who were 75 to 79 years of age with that in patients who were 80 years of age or older.


The study population included 120 patients (78 were aged 75 to 79 years and 42 were older than 80 years). The 75 to 79 years old group had more females (76% vs. 66%), whereas the 80 years of age or older group had more postoperative recurrence (35%vs. 43%). Overall response rate, median progression-free survival, and median overall survival of 75 to 79 years old and 80 years of age or older were 60.2% vs. 64.2% (p = 0.698), 14.0 months vs. 17.2 months (p = 0.40), and 29.0 months vs. 17.0 months (p = 0.02), respectively. Toxicity of EGFR-TKI was generally more severe in patients over 80 years old, and proportion of patients who reduced the dose of EGFR-TKI was larger in patient over 80 years old (13% vs 40%).


Efficacy of EGFR-TKIs did not differ in patients over 80 years old, but the overall survival was inferior to that of 75 to 79 years old. EGFR-TKI is well tolerated and had similar efficacy compared to those of the younger, even in patients older than 80 years old.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.


Has not received any funding.


Y. Goto: Consulting, advisory roles: Chugai, Boehringer Ingelheim; Speakers’ bureaus: AstraZeneca, Chugai, Boehringer Ingelheim. H. Horinouchi: Research Funding Chugai. Y. Fujiwara: Research Funding AstraZeneca, Chugai; Speakers’ bureaus: AstraZeneca. S. Kanda: Research Funding AstraZeneca; Honoraria: AstraZeneca, Chugai. N. Yamamoto: Consulting, advisory roles: Boehringer Ingelheim; Research Funding Chugai, Eisai, Boehringer Ingelheim; Speakers’ bureaus: AstraZeneca, Chugai. Y. Ohe: Research Funding AstraZeneca, Chugai; Honoraria: AstraZeneca, Chugai, Boehringer Ingelheim. All other authors have declared no conflicts of interest.